Krsnaa Diagnostics Board Approves FY26 Results, Recommends 40% Final Dividend
Krsnaa Diagnostics reported audited standalone and consolidated financial results for FY26. The company recommended a final dividend of ₹2 per share. Key auditor appointments were also approved, including M/s Kirtane & Pandit LLP as Statutory Auditors for FY27-FY31.
The announcement includes the approval of financial results and a dividend recommendation, which are material for investors. The appointment of auditors is also significant for corporate governance.
The company reported positive financial results and recommended a final dividend, which are generally viewed positively by investors. The approval of auditor appointments is a routine but necessary corporate action.
Krsnaa Diagnostics Limited announced the outcome of its Board Meeting held on May 25, 2026.
The Board approved the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026. The Statutory Auditors have issued an unmodified opinion on these financial results.
Additionally, the Board recommended a final dividend of ₹2/- per equity share (40% of face value) for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting (AGM).
Key auditor appointments and re-appointments were also approved: M/s Kirtane & Pandit LLP as Statutory Auditors for FY2026-27 to FY2030-31, M/s Mahajan & Aibara Chartered Accountants LLP as Internal Auditors for FY2026-27, Harshad S. Deshpande & Associates as Cost Auditors for FY2026-27, and M/s V. A. Dudhedia and Co. as Tax Auditors for FY2025-26. All these appointments are subject to shareholder approval where applicable.
The Board Meeting commenced at 13:30 Hrs (IST) and concluded at 18:00 Hrs (IST). The financial results are also available on the company's website.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.